Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Tirzepatide is a first-in-class, once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Given the tight link between hyperglycemia, adiposity, and cardiovascular disease, tirzepatide has rapidly gained interest as a broader cardiometabolic intervention. This narrat...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publishing
2026-06-01
|
| Schriftenreihe: | Clinical Medicine Insights: Cardiology |
| Online-Zugang: | https://doi.org/10.1177/11795468261460202 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|